Lonza Group AG (LZAGY) Discusses Divestment of Capsules and Health Ingredients Business and Focus on CDMO Transformation - Slideshow

Lonza Group AG announced plans to divest its Capsules and Health Ingredients business, marking a strategic shift in its corporate focus. The divestment aligns with Lonza’s transformation into a pure-play Contract Development and Manufacturing Organization (CDMO), prioritizing pharmaceutical and biotech services. The March 2026 announcement was shared via a slide deck during an investor event, outlining the rationale and financial implications of the restructuring. The move aims to streamline operations, enhance profitability, and sharpen Lonza’s competitive edge in the high-growth CDMO sector. Analysts note the divestment could unlock shareholder value by refocusing resources on core biopharma manufacturing capabilities.